Background: The limitations of serum testosterone and estradiol (E 2 ) measurements using nonextraction platform immunoassays (IAs) are widely recognized. Switching to more specific mass spectrometry (MS)-based methods has been advocated, but directly comparative data on the two methods are scarce. Methods: We compared serum testosterone and E 2 measurements in a large sample of middle-aged/elderly men using a common platform IA and a gas chromatography (GC)-MS method, in order to assess their limitations and advantages, and to diagnose male hypogonadism. Of subjects from the European Male Aging Study (nZ3174; age 40-79 years), peripheral serum testosterone and E 2 were analyzed using established commercial platform IAs (Roche Diagnostics E170) and in-house GC-MS methods. Results: Over a broad concentration range, serum testosterone concentration measured by IA and MS showed high correlation (RZ0.93, P!0.001), which was less robust in the hypogonadal range (!11 nmol/l; RZ0.72, P!0.001). The IA/MS correlation was weaker in E 2 measurements (RZ0.32, P!0.001, at E 2 !40.8 pmol/l, and RZ0.74, P!0.001, at E 2 O40.8 pmol/l). Using MS as the comparator method, IA ascertained low testosterone compatible with hypogonadism (!11 nmol/l), with 75% sensitivity and 96.3% specificity. The same parameters with IA for the detection of low E 2 (!40.7 pmol/l) were 13.3 and 99.3%, and for high E 2 (O120 pmol/l) 88.4 and 88.6%. Conclusion: A validated platform IA is sufficient to detect subnormal testosterone concentrations in the diagnosis of male hypogonadism. The IA used for E 2 measurements showed poor correlation with MS and may only be suitable for the detection of high E 2 in men.
Introduction
Testosterone and estradiol (E 2 ) are the two most important sex steroids in men and women respectively, and their accurate determination in serum is of crucial importance in assessing gonadal function both in clinical management and research. Immunoassay (IA) methods have been the mainstay of sex steroid measurements since their advent in the late 1960s. Most of the time they provide rapid and economical information about circulating hormone concentrations. However, the accuracy and precision of testosterone IAs, especially at the low concentrations found in children, women, and hypogonadal men, remain a concern (1, 2, 3, 4) . While the majority of IAs estimate high (adult male) concentrations sufficiently well, they usually overestimate low (female) concentrations (5) , thus reducing the specificity and sensitivity of diagnosis of female hyperadrogenism and male hypogonadism. There is no consensus on whether IAs for testosterone are able to reliably discriminate between eugonadal and hypogonadal men (1, 5, 6) . Professional societies and individual investigators have therefore emphasized the need for improved standardized methods, as well as traceability of the standards, to overcome these problems in sex steroid measurements (3, 4, 5, 6, 7, 8, 9) .
Even during the years of IA dominance, mass spectrometry (MS) was regarded as the 'gold standard' of steroid analysis, but due to its technical complexity, cost, and suboptimal sensitivity, it has only recently reached the methodological refinement required for a routine clinical chemistry laboratory. The recent technical improvements in instrumentation and the wider availability due to falling costs of equipment have made MS a competitive method with IA, having reached sufficient sensitivity yet maintaining its superior specificity in steroid hormone measurements. Therefore, opinions are being expressed to promote MS as the standard method for steroid hormone measurements (6, 9, 10) . However, MS remains more expensive and labour intensive (requiring solvent extraction), shows similar lack of between-laboratory standardisation to IA (11, 12) , and is currently still not accessible to all practitioners. It is therefore important to investigate in which clinical situations MS is necessary for the measurement of testosterone and when it is still sufficient to rely on IAs. For instance, while it is clear that measurements of testosterone by IA in children and women are unreliable, it is uncertain whether MS or IA should be the method of choice for the quantitation of testosterone to diagnose adult male hypogonadism.
Measurement of E 2 is more challenging than that of testosterone due to its much lower circulating concentration (50-100-fold less in men). Although E 2 measurements are less often required for men, high concentrations are of diagnostic importance in gynecomastia and the rare cases of feminizing tumors and aromatase excess (13) . Low E 2 concentrations are important in the assessment of osteoporosis (14, 15) and cardiovascular diseases (16, 17) , where the replacement of IAs with more specific and sensitive MS measurements is expected to be useful.
The European Male Aging Study research consortium (18) has measured testosterone and E 2 concentrations in the serum samples of a large cohort (nZ3174) of 40-79-year-old men using both an established IA and MS method. This provided a unique opportunity to compare the results obtained with these two methods and to assess the applicability of each technique for clinical diagnostics and research.
Subjects and methods

Subjects and study design
A total of 3369 community-dwelling men aged 40-79 (meanGS.D.: 60G11) years were recruited from population registers in eight European centers (Florence, Italy; Leuven, Belgium; Lodz, Poland; Malmö, Sweden; Manchester, UK; Santiago de Compostela, Spain; Szeged, Hungary; and Tartu, Estonia). Details of the research protocol have been published elsewhere (18) . Ethical approval for the study was obtained in accordance with local institutional requirements in each center, and written informed consent was obtained from the study subjects.
Hormone measurements
A single fasting morning (before 1000 h) venous blood sample was obtained and separated serum was stored at K80 8C. Measurements of testosterone and E 2 were carried out by the Modular E170 platform electrochemiluminescence IAs (Roche Diagnostics) and gas chromatography-MS (19, 20, 21, 22) . Within-and between-assay coefficients of variation (CV) in IA measurements were 1.05 and 3.72% for testosterone (at 14.4 nmol/l human serum), and 5.2 and 9.1% for E 2 (at 0.071 nmol/l human serum) respectively. The male reference range on IA for testosterone was 10.4-34.6 nmol/l and for E 2 !200 pmol/l. In MS measurements, the intra-and interassay CV were 2.9 and 3.4% for testosterone (at 1.7 nmol/l human serum), and 3.5 and 3.7% for E 2 (at 0.07 nmol/l human serum) respectively. The average recovery for steroids following extraction on MS was 102G3%, and the male reference ranges were 14.1-39.0 nmol/l for testosterone and 23-112 pmol/l for E 2 .
Sex hormone-binding globulin (SHBG) was measured by the Modular E170 platform electrochemiluminescence IAs (Roche Diagnostics). Free testosterone concentrations were derived from total testosterone, SHBG, and albumin concentrations (23) .
Statistical analysis
From the total of 3369 participants, 150 were excluded because of prevalent pituitary or testicular diseases or current use of medications that could affect pituitary/ testicular function (testosterone, dehydroepiandrosterone, antiandrogens, GnRH agonists, glucocorticoids, and psycholeptic agents) or interfere with sex steroid clearance or measurements (e.g. anticonvulsants). The reason for exclusion was their expected interference with the use of testosterone values in the diagnosis of late-onset hypogonadism (LOH; see Results). Of the remaining men, 3174 had complete data on testosterone and 3016 on E 2 with both IA and MS and were included in this analysis.
The analysis consisted of descriptive statistics to assess subject characteristics, where the data were presented as mean and S.D. for continuous variables and count (percentage for discrete variables). Distributions of total testosterone and total E 2 with both techniques were plotted via histogram. Spearman correlation measure was used to test the correlation for total testosterone and total E 2 between the two assays and within each assay. Agreement between the two assays was explored using the Bland-Altman plot (24) for limits of agreement, and bias estimation was used; this plots the % difference between MS and IA (i.e. 100! (IAKMS)/MS) against the average of the two assays ((IACMS)/2). Deviations from G20% were used as the limits of bias.
Deming regression technique (25) , which takes into account any measurement errors in the hormones, was used to additionally compare hormone concentrations between the two assays. Sensitivity and specificity of the IA measurement, using MS as the comparator method, were calculated to further explore the diagnostic accuracy of IA.
Results
Cohort characteristics
Characteristics of the analysis cohort of 3174 men are shown in Table 1 . Mean (S.D.) age of the men was 59.7 (11.0) years. The recruitment was carried out from a random general population that was relatively healthy, as shown by a variety of characteristics. Of these, 21.4% were current smokers, and in 27.1% at least one co-morbid condition was reported, which included selfreported heart conditions, high blood pressure, bronchitis, asthma, peptic ulcer, epilepsy, diabetes, cancer, liver conditions, kidney conditions, prostate diseases, and thyroid disorders. The mean (S.D.) body mass index was 27.7 (4.1) kg/m 2 and the mean (S.D.) waist circumference was 98.4 (11.1) cm.
Mass spectrometry vs immunoassay
The mean (S.D.) testosterone concentrations were very similar between IA and MS: 16.5 (5.80) and 16.6 (5.95) nmol/l respectively. E 2 concentrations were, on average, higher with IA than MS: 92.9 (28.7) and 74.1 (25.1) pmol/l respectively. There was a good agreement in the distribution of results between the two assays for testosterone (Fig. 1a) . In contrast, with E 2 (Fig. 1b) , there were more samples with concentration below 70 pmol/l with MS than IA, and above this concentration there were more E 2 samples by IA than by MS.
Bland-Altman plot
For testosterone (Fig. 2a) , there was little bias between the two methods at mean concentrations of the paired values (MS, IA) ranging from 0.175 to 46.21 nmol/l. The mean IA-MS difference (negative bias) was a low and nonsignificant K0.036 (95% confidence interval (95% CI), K0.113 to 0.040) nmol/l, with 95% limits of agreement of K4.36 to 4.29 nmol/l. Here, 9% of the testosterone concentrations by IA were more than 20% higher than those measured by MS, and 3% were over 20% lower. There was no significant trend in the relationship between the percentage bias and the average testosterone concentration of the two methods. Spearman correlation between the percentage bias and the average testosterone concentration of the two methods was 0.01 (PZ0.508). This confirms that there was no concentration-dependent loss of agreement between the two methods of testosterone quantification.
For E 2 (Fig. 2b) , there was a significant mean percentage difference (positive bias for IA) of 18.77 (95% CI, 18.11 to 19.43) pmol/l between the IA and MS measurements, with 95% limits of agreement of K18.5 to 56.1 pmol/l. The range of mean concentrations of the paired values (MS, IA) was from 17.01 to 254.65 pmol/l. The average discrepancy between the concentrations of the two methods (bias) was high; 58% of the E 2 concentrations by IA were over 20% higher than by MS, and 3% E 2 concentrations by IA were more than 20% lower than by MS. Hence, IA grossly overestimated the E 2 levels. Figure 2b shows also a trend of the relationship between the bias (percentage difference) and the average concentration of the MS and IA methods. The positive bias increased as the average of E 2 decreased with a Spearman correlation of K0.07 (P!0.001), i.e. showing an inversely concentrationdependent positive bias for IA vs MS. Figure 3 shows the scatter plots of testosterone (panel a) and E 2 (panel b) for the two methods, as well as the results from the Deming regression. The agreement between testosterone concentrations measured by IA and MS was close to the line of best fit (yZx, i.e. the line of equality), 0.97 (95% CI, 0.96 to 0.99), and the intercept was 0.41 nmol/l (95% CI, 0.18 to 0.65). For E 2 , the agreement between the two techniques deviated considerably from the line of equality, with a slope of 1.19 (95% CI, 1.15 to 1.25) and an intercept of 4.28 pmol/l (95% CI, 0.75 to 7.81). Table 2 presents the correlation coefficients between the MS and IA measurements of testosterone and E 2 at different concentrations of the hormones. With testosterone, the correlation coefficient was 0.93 in the entire cohort, 0.92 with testosterone concentrations O8 nmol/l, and 0.69 at testosterone concentrations !8 nmol/l. Using Deming regression, the agreement between testosterone concentrations measured by IA and MS with testosterone levels O8 nmol/l was close to the line of best fit, with a slope of 0.97 (95% CI, 0.95 to 0.99), and an intercept of 0.42 nmol/l (95% CI, 0.15 to 0.70). The agreement between testosterone concentrations with testosterone levels !8 nmol/l deviated more from the line of best fit, with a slope of 1.71 (95% CI, 1.04 to 2.37), and an intercept of K4.27 nmol/l (95% CI, K8.52 to K0.02). With E 2 , the correlation coefficient between the MS and IA measurements was 0.76 in the entire cohort, and 0.74 at E 2 levels above 40.8 pmol/l, but only 0.32 at concentrations below 40.8 pmol/l. Using Deming regression, the agreement between E 2 concentrations measured by IA and MS with E 2 concentrations either above 40.8 pmol/l or below 40.8 pmol/l was divergent from the line of best fit, i.e. with E 2 O40.8 pmol/l, the slope was 1.24 (95% CI, 1.18 to 1.30) and the intercept was 0.04 pmol/l (95% CI, K4.13 to 4.21); with E 2 %40.8 pmol/l, the slope was 7.89 (95% CI, 3.17 to 12.6) and the intercept was K214 pmol/l (95% CI, K382 to K46.5). Significant, though less robust, correlations were also found between the testosterone and E 2 concentrations, which were weaker or nonsignificant in the IA/IA and IA/MS comparisons. Using MS as the comparator method, we then assessed the sensitivity (% of true positives) and specificity (% of true negatives) of IA to detect low testosterone concentrations by MS at defined thresholds and to identify patients fulfilling the diagnostic criteria of LOH, i.e. low testosterone in combination with three sexual symptoms (reduced morning erections and sexual thoughts, and erectile dysfunction; Table 3 ) (26) . The sensitivity and specificity of IA to detect total testosterone !11 nmol/l were 75.0 and 96.3% respectively. To detect total testosterone !8 nmol/l, the sensitivity and specificity of IA increased slightly to 76.9 and 98.3%. If the presence of symptoms of androgen deficiency (three sexual symptoms) in addition to a total testosterone !11 nmol/l and calculated free testosterone !220 pmol/l were used as the criteria, the sensitivity and specificity of identifying LOH with the IA testosterone measurements increased to 85.5 and 99.4%. If the threshold levels of testosterone were decreased to !8 nmol/l (together with the three sexual symptoms), the respective parameters increased even further to 92.3 and 99.8%.
Deming regression
In the E 2 assay, the ability of IA to detect concentrations below 40.8 pmol/l (the lowest 5th centile for E 2 by MS) had a sensitivity of only 13.3%, with a specificity of 99.3% (Table 3 ). The IA performance to detect a concentration below 61.2 pmol/l (the lowest tertile for E 2 by MS) had a slightly better sensitivity of 25.6% and a specificity of 96.1%. In contrast, the sensitivity (88.6%) and specificity (88.4%) of E 2 IA were clearly better to detect high E 2 concentrations (O119.8 pmol/l; the highest 5th centile for E 2 by MS). Hence, IA performed especially poorly at low E 2 concentrations and grossly overestimated them, as also seen in Figs 2b and 3b.
Discussion
Our study provides thus far the largest comparative data on testosterone and E 2 measurements by IA and MS in serum samples of over 3000 men. Using MS as the comparator method for testosterone and E 2 measurements, we can conclude that testosterone measurements by IA offer good accuracy at all concentrations found in eugonadal as well as hypogonadal men. In contrast, IA provides acceptable estimates of E 2 only at the higher concentrations detected. Importantly, our data do not confirm that our platform IA for testosterone lack sensitivity and specificity in the hypogonadal range. The correlation of testosterone values between IA and MS measurements was high in the entire assay cohort, 0.93, and when testosterone level by MS was O8 nmol/l, 0.92. However, when testosterone concentrations were !8 nmol/l, the correlation was clearly lower, 0.69, indicating poorer accuracy of one or both of the methods. As compared with MS, the sensitivity of testosterone IA to detect at low testosterone concentrations (either !11 or !8 nmol/l) was 75-77%, and the specificity to detect a normal testosterone concentration was 96-98%.
The above figures are probably underestimates because the comparator MS method is not free of variability either (11, 12) . Hence, the performance of both assays may contribute to the degradation of correlation. IAs have the known problems with antibody specificity, matrix effects, and lack of linearity and functional sensitivity. The various MS methods are not identical, use diverse procedures, calibrations and technologies, and are not totally free of influence of interfering substances. Because we omitted 150 samples from men with pituitary or testicular diseases and their treatments from the analysis, our measurements do not take into account all potential interferences in the clinical samples.
Interestingly, in the context of clinical management, when the sexual symptoms were combined with low testosterone concentrations to diagnose symptomatic LOH, the sensitivity of detection by IA increased from 75 to 85.5% with testosterone !11 nmol/l (Cfree testosterone !220 pmol/l) and further to 92.3% with testosterone !8 nmol/l, probably by eliminating the impact of some functionally irrelevant borderline or erroneous testosterone concentrations (between 8 and 11 nmol/l). This emphasizes the importance of combining testosterone concentration and symptoms in the diagnosis of LOH. We can thus conclude that the IA used in our study is sufficiently sensitive and specific to discriminate between normal and low testosterone concentrations in men suspected to have LOH. However, it has to be emphasized that the testosterone IA we used was of good quality, having passed with acceptable accuracy a rigorous standardization procedure (http:// www.cdc.gov/labstandards/hs.html). All IAs used in clinical testosterone measurements are unlikely to have the same high quality.
A similar assessment of the E 2 measurements did not reveal as good correlations as with testosterone. In the entire cohort, the IA/MS correlation was 0.76, and it was 0.32 with E 2 concentrations !40.8 pmol/l and 0.74 at E 2 levels O40.8 pmol/l. It is expected that the assay performance for E 2 is worse at molar levels that are, on average, 0.4% of those of testosterone. In particular, the sensitivity of IA to detect low E 2 concentrations was poor, at 13-25%. Accordingly, IA grossly overestimated the low E 2 values. This seriously hampers the usefulness of the IA data on E 2 at low concentrations. However, the sensitivity and specificity of IA to detect E 2 concentrations in the highest 5th centile (O120 pmol/l) were acceptable (88.6 and 88.4% respectively).
Testosterone is still considered the standard assessment tool in the diagnostic approach of men with low bone density. However, with serum E 2 concentrations being more closely associated with BMD than those of testosterone (14, 15) in men, and with MS-based assays allowing more accurate and sensitive measurements at low concentrations of E 2 , their measurement is becoming increasingly useful. When comparing the clinical applicability of E 2 data in studies of BMD, Khosla et al. (27) concluded that although the MS data provide more accurate measurements in men, the applicability of the E 2 IA data for bone data is generally valid. Hence, the necessity of switching E 2 measurements from IA to MS is somewhat relative, admitting that the latter technique yields more accurate, but not necessarily clinically more useful results. Our data, however, show that serum testosterone and E 2 concentrations are not highly correlated. A case can be made to develop clinical algorithms incorporating accurate measurement of E 2 as part of the evaluation of osteoporosis in men. Moreover, recent epidemiologic studies in men and women have demonstrated associations between low sex hormone concentrations (including E 2 ) and the risk of cardiovascular disease in both sexes (16, 17, 28, 29) , suggesting another indication where more reliable methods for E 2 measurement should be used. It should be acknowledged that in everyday clinical practice, the higher concentrations of E 2 in men that may occur in gynecomastia and the rare cases of feminising tumors and aromatase excess can be discriminated with sufficient accuracy by IA. Although MS, in general, is more specific and has lower intra-and interassay variability than IA, it faces similar inter-laboratory variability issues as IA (11, 12) . All MS methods are not equal; like IA, they represent a heterogeneous group of measurements with significant differences in performance. One study comparing several established MS methods for the determination of testosterone in serum found overall CV of up to 33% at low concentrations, up to 15% at O1.5 nmol/l, and 1.4-11.4% at concentrations O3.5 nmol/l (11) . Nevertheless, the variability in testosterone results with MS methods in most comparisons is substantially smaller than those reported for platform IAs (1, 5, 30, 31) . Whether this difference translates into improved clinical relevance requires additional data and experience. A very recent study comparing total testosterone assays in women concluded that the results obtained by IA and MS were comparable, and there is significant variability and poor precision also between various MS methods at low Table 3 Sensitivity and specificity of IA in detection of low testosterone levels (panels A and B), diagnosing LOH (panels C and D), and detection of low and high E 2 (panels E, F and G), using MS as the reference method. levels (12) . Hence, switching from IA to MS is not a guaranteed solution to improve the quality of sex steroid measurements at low concentrations. Improvements in performance and standardization in platform IAs are feasible alternatives that are already being implemented by some manufacturers. It is a major investment to abandon IA technology in favor of MS, and the reasons for this must be tangible and supported by evidence rather than conjecture. Our results suggest that, at least in men, IA can be as good as MS in the clinically important discrimination between eugonadal and hypogonadal men, especially when combined with clinical signs of androgen deficiency. The variability and imprecision of E 2 measurements by MS is smaller than by IA, and it is clear that MS is superior to IA in the measurement of this hormone, especially at low concentrations. It seems prudent to conclude that the selection of an assay should be driven by the measurement performance in light of the clinical need and not by assay technology.
MS
In conclusion, the comparison of measurements of serum testosterone and E 2 in the largest cohort so far of adult male samples indicates that clinically relevant results on serum testosterone for the diagnosis of hypogonadism can be obtained both with well-validated IA and MS assays. Our findings do not support a mandatory requirement, on either analytical or clinical grounds, to switch from good-quality IAs to MS in the measurements of testosterone in male subjects. In contrast, clinicians should be aware of the unreliability of apparently low E 2 results in men obtained by IA. Finally, assay performance is more important than assay technology. 
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